Although multiple studies on MYC/BCL2 DHL have been published, to date no study has systemically compared the clinicopathologic features and prognostic factors between patients with de novo MYC/BCL2 DHL versus those patients with a history of follicular lymphoma (FL). The gene discussed is MYC; the disease is follicular lymphoma.